Group 1 - The core viewpoint of the article highlights that Yidu Technology (02158) has been actively repurchasing its shares for three consecutive days, signaling positive market sentiment [1] - The company repurchased 280,000 shares at a price of HKD 5.18 per share on December 5, with a total repurchase amount of HKD 1.4 million, bringing the total shares repurchased to approximately 853,000 and the cumulative repurchase amount exceeding HKD 4.3 million [1] - Yidu Technology reported a healthy revenue growth for the fiscal year 2026, achieving total revenue of RMB 358 million, which represents a year-on-year increase of 8.7% [1] Group 2 - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, indicating significant improvement in profitability and operational efficiency [1] - The company has nearly reached breakeven on its financial statements, achieving this key financial milestone about a year earlier than previously anticipated by management [1] - A new collaboration has been initiated between Yidu Technology and Tsinghua Changgung Hospital to establish a digital technology research and development platform, marking a new phase in their partnership in the field of medical artificial intelligence [1]

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on December 5, 2023, spending HKD 1.45 million to repurchase 280,000 shares at a price range of HKD 5.15 to 5.20 per share [1] Group 1 - The total expenditure for the share buyback was HKD 1.45 million [1] - The number of shares repurchased was 280,000 [1] - The price range for the repurchased shares was between HKD 5.15 and HKD 5.20 [1]

智通财经APP讯，医渡科技(02158)发布公告，该公司于2025年12月5日斥资145.12万港元回购28万股股 份，每股回购价格为5.15-5.2港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔 ...

Group 1 - Company announced a share buyback of 181,000 shares at a cost of HKD 931,600 on December 4, 2025 [2][4]

Group 1 - The core viewpoint of the news is that Yidu Technology (2158) is demonstrating strong growth and operational efficiency, as evidenced by its recent share buybacks and positive financial performance [1][2] - The company repurchased 181,000 shares at an average price of HKD 5.15, totaling over HKD 930,000, marking a continuous buyback trend with a cumulative amount nearing HKD 3 million [1] - For the fiscal year 2026, Yidu Technology reported total revenue of RMB 358 million, reflecting an 8.7% year-on-year growth, with adjusted EBITDA reaching approximately RMB 54 million, doubling from the previous year [1] Group 2 - The management highlighted that the AI medical model technology has entered a new phase of "multi-point blossoming and large-scale landing," with significant deployments in over 30 top-tier hospitals [2] - The AI tool "Copilot" is being utilized nearly 1,000 times daily in individual hospitals, integrating into actual workflows [2] - The diagnostic accuracy of the TNM staging assessment tool has improved significantly, with T-stage accuracy rising from 58% to 90%, reaching the level of chief physicians [2] Group 3 - Capital market analysts are optimistic about Yidu Technology, with Everbright Securities noting breakthroughs in AI medical innovation and the establishment of a "data + algorithm + scenario" closed-loop system [2] - Citigroup maintained a "Buy" rating for the company with a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [2] Group 4 - As of the latest market close, Yidu Technology's stock price was HKD 5.15, reflecting a 0.98% increase [3]

Group 1 - The company repurchased 181,000 shares at an average price of HKD 5.15, totaling over HKD 930,000, marking the second consecutive day of buybacks, with a cumulative total of approximately 573,000 shares and nearly HKD 3 million in total repurchases [1] - Since September 26, the company has completed 12 repurchase transactions, with a cumulative repurchase amount exceeding HKD 25 million [1] - The company reported total revenue of RMB 358 million for the fiscal year 2026, representing a year-on-year growth of 8.7%, with adjusted EBITDA reaching approximately RMB 54 million, doubling from the same period last year [1] Group 2 - The management highlighted that the AI medical model technology has entered a new phase of "multiple blooms and large-scale implementation," evidenced by deep deployment in over 30 top-tier hospitals nationwide [2] - The diagnostic accuracy of the developed TNM staging assessment tool has significantly improved, with T-stage accuracy rising from 58% to 90%, reaching the level of chief physicians [2] - Brokerages are releasing positive signals, with Everbright Securities noting the company's breakthroughs in AI medical innovation and Citigroup maintaining a "buy" rating with a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [2]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, intending to repurchase 181,000 shares at a cost of HKD 931,600 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 | | | 致：香港交易及結算所有限公司 公司名稱: 醫渡科技有限公司 呈交日期: 2025年12月 ...